1 Min Read
March 6 (Reuters) - Amgen Inc
* Amgen highlights Landmark Repatha (evolocumab) cardiovascular outcomes study amongst data to be presented at acc.17 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.